FINWIRES · TerminalLIVE
FINWIRES

$KLRS

3 stories mentioning KLRSUpdated 22d ago

Every FINWIRES story that references KLRS, newest first.

Wire

Top Midday Gainers

Travelers' (TRV) Q2 earnings unexpectedly increased year over year, while the property and casualty insurer's written premiums came in ahead of market estimates.Shares jumped 8.3% as intraday trading volume climbed to over 2.38 million from a daily average of about 1.70 million.Kalaris Therapeutics (KLRS) said Friday that additional patients from its phase 1a trial of TH103 in neovascular age-related macular degeneration showed improvements in vision and retinal anatomy.Shares surged 18% as intraday trading volume jumped to over 9.83 million from a daily average of about 79,000.Callan JMB's (CJMB) shares rose 40% amid heavy trading after the company announced a partnership with Alabama State University to support the development of an integrated pharmaceutical manufacturing ecosystem.More than 41.8 million shares of the company traded intraday, compared with a daily average of about 373,000.Price: $365.63, Change: $+27.81, Percent Change: +8.23%

$CJMB$KLRS$TRV
Research

Wedbush Initiates Kalaris Therapeutics at Outperform With $17 Price Target

Kalaris Therapeutics (KLRS) has an average rating of buy and mean price target of $19, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$KLRS
Research

Morgan Stanley Initiates Kalaris Therapeutics at Overweight

Kalaris Therapeutics (KLRS) has an average rating of buy and mean price target of $19.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$KLRS

Track with the FINWIRES app suite